Antiepileptic drugs in clinical development.
Ramsay
R E
RE
Department of Neurology and Psychiatry, University of Miami School of Medicine, FL.
Slater
J D
JD
D000085:Acetates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000588:Amines; D000614:Aminocaproates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D000078328:Felbamate; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D009557:Nipecotic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D000078308:Tiagabine; D000077236:Topiramate; D014227:Triazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000614:Aminocaproates; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D009557:Nipecotic Acids; D048448:Phenylcarbamates; D011409:Propylene Glycols; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D020888:Vigabatrin; D000077213:Lamotrigine; D000078328:Felbamate; D000078308:Tiagabine